LY3023414

samotolisib · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for LY3023414, covering 2016-11-04 to 2023-09-11. Get the full timeline:

Most recent: Clinical Trial Update: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer [Phase 2]